A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Inclusion Criteria: * normal renal function or renal impairment * stable hemodialysis treatment for at least 3 months before screening and able to tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of \>200mL/min (cohort 3 only) * neither pregnant nor lactating * HbA1c 6-10.5% inclusive * females of childbearing potential must be practicing adequate contraception. Exclusion Criteria: * inability to meet the PK objectives of the study * history of hypoglycemia unawareness or severe hypoglycemia * liver function tests greater than or equal to 2 times the ULN * clinically significant cardiovascular and/or cerebrovascular disease * positive test results for hepatitis B, hepatitis C, or HIV * documented hypertension or hypotension at screening * known hepatic or biliary abnormalities * current use of sulfonylureas * active history of tobacco use within 6 months before screening * donation of blood in excess of 500mL within 56 days before albiglutide dosing * receipt of any investigational drug within the 30days or 5 half lives, whichever is longer, before dosing * previous or current receipt of exenatide or any other GLP-1 agonist